印度保护研究参与者的新政策。 - Suppr

Suppr

超能文献

India's new policy to protect research participants.

作者信息

Sugarman Jeremy, Bhan Anant, Bollinger Robert, Gupta Amita

出版信息

BMJ. 2013 Jul 31;347:f4841. doi: 10.1136/bmj.f4841.

DOI:10.1136/bmj.f4841

PMID:23903456

Abstract

摘要

相似文献

India's new policy to protect research participants.印度保护研究参与者的新政策。

BMJ. 2013 Jul 31;347:f4841. doi: 10.1136/bmj.f4841.

New regulations on compensation for injury and death in drug trials.药物试验中伤亡赔偿新规定。

Indian J Med Ethics. 2013 Apr-Jun;10(2):76-9. doi: 10.20529/IJME.2013.026.

India's regulatory reforms on compensation for clinical trial injuries and deaths: urgent need for revisiting.印度关于临床试验伤害与死亡赔偿的监管改革：亟需重新审视。

Indian J Med Ethics. 2013 Jul-Sep;10(3):195-7. doi: 10.20529/IJME.2013.057.

Campaigners criticise India's new system for compensating clinical trial deaths.

BMJ. 2014 Dec 29;349:g7806. doi: 10.1136/bmj.g7806.

Acoustic separation and biomedical research: lessons from Indian regulation of compensation for research injury.声学分离与生物医学研究：印度研究伤害赔偿监管的经验教训。

J Law Med Ethics. 2015 Spring;43(1):105-15. doi: 10.1111/jlme.12199.

Justice for injured research subjects.为受伤害的研究对象伸张正义。

N Engl J Med. 2012 Jul 5;367(1):6-8. doi: 10.1056/NEJMp1205623.

Universal and uniform protection of human subjects in research: also a fallacy in some developing countries.在研究中对人类受试者进行普遍和统一的保护：在一些发展中国家也是一种谬论。

Am J Bioeth. 2008 Nov;8(11):19-20. doi: 10.1080/15265160802478479.

New rules for clinical trial-related injury and compensation.临床试验相关伤害与赔偿的新规定。

Indian J Med Ethics. 2013 Jul-Sep;10(3):197-200. doi: 10.20529/IJME.2013.058.

The ethical neuroscientist.有道德的神经科学家。

Nat Neurosci. 2008 Mar;11(3):239. doi: 10.1038/nn0308-239.

Ethical human-research protections: not universal and not uniform.伦理层面的人体研究保护措施：并非普遍适用，也不统一。

Am J Bioeth. 2008 Nov;8(11):21-2. doi: 10.1080/15265160802516864.

引用本文的文献

Towards achieving transnational research partnership equity: lessons from implementing adaptive platform trials in low- and middle-income countries.迈向实现跨国研究伙伴关系公平：在低收入和中等收入国家开展适应性平台试验的经验教训。

Wellcome Open Res. 2023 Dec 6;8:120. doi: 10.12688/wellcomeopenres.18915.2. eCollection 2023.

Regulating international clinical research: an ethical framework for policy-makers.规范国际临床研究：政策制定者的伦理框架。

BMJ Glob Health. 2020 May;5(5). doi: 10.1136/bmjgh-2020-002287.

Challenges in conducting a community-based influenza vaccine trial in a rural community in northern India.在印度北部农村社区进行基于社区的流感疫苗试验面临的挑战。

Hum Vaccin Immunother. 2018;14(8):1909-1913. doi: 10.1080/21645515.2018.1460182. Epub 2018 May 9.

Investigators' viewpoint of clinical trials in India: Past, present and future.印度临床试验的研究者观点：过去、现在与未来。

Perspect Clin Res. 2017 Jan-Mar;8(1):31-36. doi: 10.4103/2229-3485.198552.

Clinical Research Environment in India: Challenges and Proposed Solutions.印度的临床研究环境：挑战与建议的解决方案

J Clin Res Bioeth. 2014 Nov 1;5(6):1-8. doi: 10.4172/2155-9627.1000201.

Ethics Standards (HRPP) and Public Partnership (PARTAKE) to Address Clinical Research Concerns in India: Moving Toward Ethical, Responsible, Culturally Sensitive, and Community-Engaging Clinical Research.印度解决临床研究问题的伦理标准（HRPP）与公共伙伴关系（PARTAKE）：迈向符合伦理、负责任、具有文化敏感性且社区参与型的临床研究

J Clin Res Bioeth. 2014 Sep 7;5(5):195.

Compensation for clinical trial-related injury and death in India: challenges and the way forward.印度临床试验相关损伤与死亡的补偿：挑战与未来之路

Drug Saf. 2014 Dec;37(12):995-1002. doi: 10.1007/s40264-014-0230-3.

Clinical trials in India: At uncertain crossroads?印度的临床试验：处于不确定的十字路口？

Indian J Med Paediatr Oncol. 2014 Apr;35(2):133-5. doi: 10.4103/0971-5851.138947.

Pioglitazone suspension and its aftermath: A wake up call for the Indian drug regulatory authorities.吡格列酮悬浮液及其后果：给印度药品监管当局敲响的警钟。

J Pharmacol Pharmacother. 2013 Oct;4(4):227-9. doi: 10.4103/0976-500X.119705.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验